PEG-MGF is the PEGylated form of MGF (Mechano Growth Factor), and the case for it is almost
entirely about pharmacokinetics rather than any new biology. This monograph separates what the
PEGylation actually changes from what is still unproven about the underlying peptide.
Chemical identity & structure.
MGF is a splice variant of IGF-1 — specifically IGF-1Ec, produced when muscle is subjected to
mechanical overload or damage. It differs from systemic IGF-1 by a unique C-terminal E-domain
peptide, and it is that E-domain fragment that is typically synthesised and sold as "MGF".
PEG-MGF is the same peptide with a polyethylene-glycol (PEG) moiety covalently attached.
Native MGF is cleared from blood in minutes; PEGylation is a well-established pharmaceutical
technique that increases hydrodynamic size, slows renal clearance, and extends the circulating
half-life from minutes toward hours.
Mechanism of action.
The MGF E-domain is reported in cell-culture and rodent work to act on muscle satellite (stem)
cells — promoting their proliferation and delaying differentiation, which in principle expands
the pool of myonuclei available for repair. This is mechanistically distinct from mature IGF-1
signalling through the IGF-1 receptor, and the exact receptor/target for the E-domain fragment
is still not fully established. PEGylation is not thought to change the mechanism — only how long
the peptide persists to act.
Key research findings.
The evidence base is preclinical: rodent and in-vitro studies reporting satellite-cell activation
and effects in models of muscle injury and overload. PEGylated versions are reported to produce a
more durable exposure than unmodified MGF in animal work. The breadth of claims made for MGF in
the consumer market runs far ahead of this evidence.
The research / citation base.
There are no completed human clinical trials of PEG-MGF. The peptide is not an approved drug
anywhere. The literature is small, animal-dominated, and does not establish human efficacy or
safety. Any presentation of PEG-MGF as a proven human muscle therapy overstates what exists.
Human clinical trial data.
No human clinical trial has established administration parameters for PEG-MGF; VialTalk does not provide community-sourced dosing.
As a lyophilised peptide it is stored cold (refrigerated, protected from light).
Quality & sourcing notes.
A meaningful COA should confirm identity (mass spectrometry consistent with the expected MGF
E-domain plus PEG adduct) and purity (HPLC). Because "MGF", "PEG-MGF" and full-length IGF-1Ec are
routinely conflated in this market, identity verification matters more than usual. Treat any vial
without a batch-specific COA as unverified.
*Research-use note: This monograph is an educational summary of the published research literature.
PEG-MGF is not an approved drug; it is described here for research context only. Nothing here is
medical advice or a usage recommendation.*
